Abstract:Background: with the evolution of curative treatment regimen, the rate of complete remission achieved in patients with diffuse aggressive non-Hodgkin lymphoma is continuously rising. It is achievable at the end of primary treatment in about 60-80%. On the other hand relapse is very common in the 1 st two years after end of primary treatment in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, that is to say, about 20-25% of patients relapse after complete response. Use of routine surveillance imag… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.